Quinine Dihydrochloride Injection 2ml:600mg

Quinine Dihydrochloride Injection 2ml:600mg: What the Published Guidance Says

Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.

Quinine Dihydrochloride Injection 2ml:600mg is specified against its own monograph, pack size and market registration, so the guidance below is worth reading together with the Malaria & ACTs range overview.

• For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual
• Pre-referral rectal artesunate buys time in the first 24 hours Because the risk of death from severe malaria is greatest during the first day, WHO recommends a single pre-referral dose by the parenteral or intrarectal route. Artesunate suppositories are given at 10 mg/kg as a single dose, in 50 mg or 200 mg formulations. The Model List carries a 100 mg rectal dosage form, restricted to pre-referral treatment of severe malaria only. WHO — Malaria case management: operations manual
• The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)

Each point above is reproduced because it has a practical consequence for Quinine Dihydrochloride Injection 2ml:600mg: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.

How Quinine Dihydrochloride Injection 2ml:600mg Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Release testing for Quinine Dihydrochloride Injection 2ml:600mg follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

• Testing for description and identification
• Testing for assay of the active substance
• Testing for related substances and impurities
• Testing for dissolution or release profile (solid oral forms)
• Testing for uniformity of dosage units
• Testing for water content and pH where applicable

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Quinine Dihydrochloride Injection 2ml:600mg Is Packed, Labelled and Shipped

• Pack size: 2mL sterile glass ampoule or vial (with rubber stopper and aluminum seal). Non-standard pack sizes can be quoted against your artwork.
• Storage: Store below 25°C, protected from light. Do not freeze. Keep ampoules/vials in outer carton until use..
• Shelf life: 24 months (unopened). Stability data for the marketed pack is included in the dossier.
• Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
• Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Quinine Dihydrochloride Injection 2ml:600mg

The legal manufacturer named on every document for Quinine Dihydrochloride Injection 2ml:600mg is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.

• Method validation, stability protocol and the shelf-life justification for the marketed pack.
• Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
• Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
• Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
• Batch manufacturing and packaging records released for inspection on request during supplier audits.

Quinine Dihydrochloride Injection 2ml:600mg is presented here against ACT regimens named in the WHO Model List of Essential Medicines. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.